Lasofoxifene

Lasofoxifene
Clinical data
Trade namesFablyn
Routes of
administration		By mouth
Drug classSelective estrogen receptor modulator
ATC code
Identifiers
  • (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H31NO2
Molar mass413.55 g/mol
563.64 g/mol (tartrate) g·mol−1
3D model (JSmol)
  • O(c1ccc(cc1)[C@@H]4c2ccc(O)cc2CC[C@@H]4c3ccccc3)CCN5CCCC5
  • InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1 checkY
  • Key:GXESHMAMLJKROZ-IAPPQJPRSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy,[1][2] and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published in The Journal of the National Cancer Institute.

  1. ^ Gennari L, Merlotti D, Martini G, Nuti R (September 2006). "Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis". Expert Opinion on Investigational Drugs. 15 (9): 1091–103. doi:10.1517/13543784.15.9.1091. PMID 16916275. S2CID 20693299.
  2. ^ "Fablyn (Lasofoxifene tartrate) FDA Approval Status".